atezolizumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
humanized origin 5151 1380723-44-3

Description:

MoleculeDescription

Synonyms:

  • atezolizumab
  • tecentriq
  • RG7446
  • MPDL3280A
  • atezolizumab (genetical recombination)
A monoclonal antibody that targets programmed death-ligand 1 (CD274 ANTIGEN) and is used to treat urothelial carcinoma, the most common type of bladder cancer.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Sept. 20, 2017 EMA Roche Registration GmbH
May 18, 2016 FDA GENENTECH INC
Jan. 19, 2018 PMDA Chugai Pharmaceutical Co., Ltd.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 380.51 25.47 308 19748 118141 63350825
Hypothyroidism 375.77 25.47 208 19848 42424 63426542
Neutrophil count decreased 374.68 25.47 229 19827 56177 63412789
Pneumonitis 358.24 25.47 189 19867 35033 63433933
Disease progression 356.32 25.47 301 19755 122457 63346509
Death 306.91 25.47 475 19581 373906 63095060
Anaemia 296.34 25.47 411 19645 293019 63175947
Hyperthyroidism 240.09 25.47 109 19947 14564 63454402
Pyrexia 207.36 25.47 457 19599 470021 62998945
Colitis 201.08 25.47 147 19909 48381 63420585
Interstitial lung disease 194.24 25.47 159 19897 61749 63407217
Adrenal insufficiency 167.60 25.47 91 19965 17824 63451142
Immune-mediated enterocolitis 153.72 25.47 47 20009 2064 63466902
Immune-mediated hepatitis 150.60 25.47 42 20014 1329 63467637
Platelet count decreased 146.72 25.47 182 19874 115940 63353026
Neutropenic sepsis 138.66 25.47 78 19978 16360 63452606
Myocarditis 132.85 25.47 65 19991 10260 63458706
Hypokalaemia 128.39 25.47 161 19895 103643 63365323
Neutropenia 116.88 25.47 203 19853 174802 63294164
Mucosal inflammation 113.63 25.47 104 19952 46824 63422142
Hepatic function abnormal 111.43 25.47 93 19963 37049 63431917
Drug ineffective 108.40 25.47 103 19953 1044662 62424304
Thrombocytopenia 107.04 25.47 180 19876 150977 63317989
Encephalitis 105.63 25.47 53 20003 8827 63460139
Skin candida 104.34 25.47 33 20023 1622 63467344
Pain 100.14 25.47 55 20001 740573 62728393
Metastases to central nervous system 99.32 25.47 58 19998 13047 63455919
Type 1 diabetes mellitus 94.62 25.47 38 20018 3752 63465214
Lymphocyte count decreased 93.33 25.47 77 19979 30180 63438786
Proteinuria 90.77 25.47 63 19993 19082 63449884
Systemic immune activation 86.09 25.47 16 20040 70 63468896
Sepsis 83.72 25.47 163 19893 152960 63316006
Joint swelling 83.60 25.47 5 20051 327661 63141305
Hepatic failure 82.38 25.47 77 19979 35579 63433387
Embolism 81.91 25.47 43 20013 7863 63461103
Rash maculo-papular 81.74 25.47 73 19983 31823 63437143
Cytokine release syndrome 77.15 25.47 51 20005 14263 63454703
Intentional product use issue 75.89 25.47 141 19915 127751 63341215
Ascites 75.54 25.47 78 19978 40650 63428316
White blood cell count decreased 74.72 25.47 147 19909 138957 63330009
Swelling 74.07 25.47 3 20053 275375 63193591
Abdominal discomfort 73.27 25.47 8 20048 320877 63148089
Hepatitis 69.85 25.47 74 19982 39714 63429252
Aspartate aminotransferase increased 68.54 25.47 111 19945 90166 63378800
Constipation 67.30 25.47 189 19867 224754 63244212
Hypomagnesaemia 66.27 25.47 62 19994 28675 63440291
Hyperglycaemia 65.02 25.47 73 19983 41794 63427172
Peripheral sensory neuropathy 64.57 25.47 36 20020 7415 63461551
Alanine aminotransferase increased 63.55 25.47 116 19940 103654 63365312
Enterocolitis 62.79 25.47 36 20020 7822 63461144
Product dose omission issue 61.53 25.47 3 20053 234310 63234656
Encephalopathy 57.70 25.47 66 19990 38554 63430412
Myositis 57.30 25.47 36 20020 9230 63459736
Neuropathy peripheral 56.10 25.47 116 19940 113551 63355415
Tubulointerstitial nephritis 55.90 25.47 48 20008 19855 63449111
Hyponatraemia 54.99 25.47 114 19942 111786 63357180
Autoimmune hepatitis 54.99 25.47 34 20022 8476 63460490
Immune-mediated encephalitis 54.28 25.47 13 20043 221 63468745
Drug hypersensitivity 53.29 25.47 16 20040 310671 63158295
Small intestinal obstruction 53.09 25.47 45 20011 18292 63450674
Thyroiditis 52.29 25.47 22 20034 2444 63466522
Rheumatoid arthritis 51.62 25.47 9 20047 253810 63215156
Drug interaction 51.55 25.47 6 20050 229125 63239841
Decreased appetite 51.29 25.47 185 19871 250867 63218099
Treatment failure 50.84 25.47 3 20053 199040 63269926
Autoimmune haemolytic anaemia 50.46 25.47 26 20030 4575 63464391
Weight increased 49.36 25.47 11 20045 260781 63208185
Cholangitis 48.55 25.47 27 20029 5534 63463432
Pleural effusion 48.20 25.47 97 19959 93113 63375853
Myasthenia gravis 47.69 25.47 25 20031 4556 63464410
Drug-induced liver injury 47.46 25.47 61 19995 40161 63428805
Adrenocorticotropic hormone deficiency 46.77 25.47 13 20043 406 63468560
Pancytopenia 46.74 25.47 98 19958 96835 63372131
Maternal exposure during pregnancy 46.55 25.47 7 20049 220055 63248911
Guillain-Barre syndrome 45.60 25.47 23 20033 3870 63465096
Metastases to meninges 44.67 25.47 20 20036 2582 63466384
Encephalitis autoimmune 44.50 25.47 17 20039 1469 63467497
Immune-mediated pancreatitis 44.19 25.47 10 20046 131 63468835
Nasopharyngitis 43.76 25.47 13 20043 254244 63214722
Toxicity to various agents 43.74 25.47 12 20044 247238 63221728
Musculoskeletal stiffness 43.68 25.47 4 20052 184614 63284352
Diarrhoea 43.55 25.47 379 19677 714987 62753979
Product use issue 42.34 25.47 9 20047 220511 63248455
Nervous system disorder 42.32 25.47 40 20016 18726 63450240
Meningitis 42.17 25.47 27 20029 7150 63461816
Nephritis 42.11 25.47 19 20037 2497 63466469
Immune-mediated lung disease 41.21 25.47 13 20043 633 63468333
Oligoastrocytoma 39.73 25.47 7 20049 21 63468945
Haemophagocytic lymphohistiocytosis 39.08 25.47 30 20026 10597 63458369
Acute kidney injury 37.77 25.47 174 19882 263241 63205725
Hypopituitarism 37.52 25.47 14 20042 1134 63467832
Dehydration 37.29 25.47 130 19926 173224 63295742
Hydronephrosis 36.82 25.47 29 20027 10633 63458333
Radiation pneumonitis 36.52 25.47 15 20041 1568 63467398
Myelosuppression 36.23 25.47 41 20015 23662 63445304
Tumour hyperprogression 35.62 25.47 8 20048 101 63468865
Condition aggravated 35.52 25.47 45 20011 402172 63066794
Hypersensitivity 33.58 25.47 26 20030 292659 63176307
Arthralgia 32.97 25.47 83 19973 569627 62899339
Peripheral swelling 32.63 25.47 22 20034 265920 63203046
Hypoxia 31.83 25.47 63 19993 59729 63409237
Sinusitis 31.70 25.47 16 20040 226637 63242329
Malignant neoplasm progression 31.70 25.47 76 19980 82045 63386921
Metastases to liver 31.32 25.47 38 20018 23601 63445365
Hypophysitis 31.12 25.47 14 20042 1827 63467139
Insomnia 30.40 25.47 15 20041 215237 63253729
General physical health deterioration 30.31 25.47 135 19921 201267 63267699
Off label use 29.58 25.47 334 19722 674128 62794838
Erythema multiforme 29.52 25.47 25 20031 10144 63458822
Therapy partial responder 28.50 25.47 25 20031 10633 63458333
Transaminases increased 27.16 25.47 41 20015 31326 63437640
Autoimmune colitis 26.72 25.47 9 20047 540 63468426
Hypertension 26.67 25.47 165 19891 279138 63189828
Blood creatinine increased 26.39 25.47 74 19982 87770 63381196
Peripheral motor neuropathy 25.95 25.47 12 20044 1669 63467297
Pericardial effusion 25.62 25.47 39 20017 30019 63438947
Blister 25.52 25.47 5 20051 129809 63339157

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Disease progression 398.30 19.78 447 25880 107630 34822974
Hypothyroidism 345.34 19.78 208 26119 20694 34909910
Pneumonitis 315.36 19.78 236 26091 33642 34896962
Adrenal insufficiency 302.05 19.78 166 26161 13881 34916723
Interstitial lung disease 298.41 19.78 303 26024 64979 34865625
Proteinuria 296.32 19.78 181 26146 18461 34912143
Ascites 197.90 19.78 208 26119 46363 34884241
Oesophageal varices haemorrhage 197.02 19.78 78 26249 3068 34927536
Hepatic function abnormal 190.03 19.78 199 26128 44164 34886440
Hyperthyroidism 179.21 19.78 107 26220 10459 34920145
Myelosuppression 176.45 19.78 133 26194 19132 34911472
Neutrophil count decreased 175.24 19.78 204 26123 50900 34879704
Colitis 164.63 19.78 171 26156 37579 34893025
Tumour haemorrhage 159.87 19.78 66 26261 2896 34927708
Pyrexia 147.40 19.78 566 25761 332447 34598157
Death 140.52 19.78 631 25696 397418 34533186
Drug interaction 138.21 19.78 8 26319 225938 34704666
Myocarditis 135.45 19.78 99 26228 13583 34917021
Febrile neutropenia 133.05 19.78 308 26019 136541 34794063
Encephalitis 129.42 19.78 76 26251 7201 34923403
Cholangitis 117.00 19.78 76 26251 8613 34921991
Toxicity to various agents 114.14 19.78 10 26317 200352 34730252
Immune-mediated enterocolitis 104.17 19.78 48 26279 2751 34927853
Autoimmune hepatitis 100.53 19.78 54 26273 4306 34926298
Liver disorder 98.75 19.78 123 26204 32874 34897730
Varicose vein ruptured 91.11 19.78 19 26308 58 34930546
Myositis 88.25 19.78 73 26254 11997 34918607
Therapy partial responder 84.95 19.78 65 26262 9551 34921053
Nephritis 84.91 19.78 40 26287 2411 34928193
Radiation pneumonitis 82.08 19.78 40 26287 2600 34928004
Immune-mediated hepatitis 79.36 19.78 37 26290 2178 34928426
Immune-mediated lung disease 77.63 19.78 33 26294 1558 34929046
Tumour rupture 77.30 19.78 21 26306 240 34930364
Hepatic encephalopathy 74.01 19.78 72 26255 14613 34915991
Platelet count decreased 72.19 19.78 226 26101 119491 34811113
Varices oesophageal 71.49 19.78 41 26286 3714 34926890
Metastases to central nervous system 71.46 19.78 55 26272 8150 34922454
Hepatitis 71.33 19.78 89 26238 23815 34906789
Blood bilirubin increased 70.29 19.78 113 26214 38183 34892421
Aspartate aminotransferase increased 67.29 19.78 154 26173 67629 34862975
Type 1 diabetes mellitus 66.71 19.78 41 26286 4217 34926387
Autoimmune colitis 66.50 19.78 26 26301 988 34929616
Hypopituitarism 66.25 19.78 33 26294 2249 34928355
Hypophysitis 66.20 19.78 33 26294 2253 34928351
Hyponatraemia 65.24 19.78 172 26155 82519 34848085
Anaemia 64.01 19.78 345 25982 232990 34697614
Enterocolitis 63.85 19.78 51 26276 7975 34922629
Decreased appetite 62.19 19.78 269 26058 166123 34764481
Condition aggravated 61.73 19.78 34 26293 192162 34738442
Tumour hyperprogression 60.24 19.78 14 26313 79 34930525
Hepatic failure 59.45 19.78 99 26228 34432 34896172
Alanine aminotransferase increased 58.64 19.78 163 26164 80652 34849952
Erythema multiforme 58.46 19.78 50 26277 8599 34922005
Off label use 54.33 19.78 517 25810 419007 34511597
Paraneoplastic neurological syndrome 52.64 19.78 11 26316 34 34930570
Drug ineffective 51.27 19.78 175 26152 456576 34474028
Liver carcinoma ruptured 50.24 19.78 14 26313 177 34930427
Adrenocorticotropic hormone deficiency 47.39 19.78 20 26307 927 34929677
Fulminant type 1 diabetes mellitus 45.20 19.78 19 26308 872 34929732
Pneumonia 43.49 19.78 440 25887 362187 34568417
Drug hypersensitivity 43.23 19.78 5 26322 80524 34850080
Tumour thrombosis 42.86 19.78 11 26316 99 34930505
Embolism 42.50 19.78 40 26287 7789 34922815
Metastases to meninges 42.13 19.78 21 26306 1433 34929171
Systemic immune activation 42.11 19.78 9 26318 32 34930572
Peripheral sensory neuropathy 41.50 19.78 37 26290 6723 34923881
Depression 41.36 19.78 11 26316 97087 34833517
Tubulointerstitial nephritis 41.27 19.78 64 26263 20960 34909644
Hyperhidrosis 39.89 19.78 5 26322 75687 34854917
Dizziness 39.38 19.78 65 26262 218456 34712148
Haemoglobin decreased 39.27 19.78 21 26306 120751 34809853
Encephalitis autoimmune 39.03 19.78 16 26311 689 34929915
Immune-mediated encephalitis 38.58 19.78 12 26315 227 34930377
Cerebral infarction 38.56 19.78 72 26255 27383 34903221
Urinary occult blood 38.50 19.78 7 26320 7 34930597
Polymyalgia rheumatica 38.49 19.78 20 26307 1490 34929114
Tremor 37.85 19.78 8 26319 82579 34848025
Tumour pseudoprogression 37 19.78 14 26313 486 34930118
Fall 36.88 19.78 60 26267 202825 34727779
Feeling abnormal 36.37 19.78 3 26324 63232 34867372
Drug-induced liver injury 36.07 19.78 72 26255 28760 34901844
Peripheral swelling 35.94 19.78 7 26320 76534 34854070
Inappropriate schedule of product administration 35.70 19.78 3 26324 62293 34868311
Tumour necrosis 35.55 19.78 18 26309 1270 34929334
Neutropenic sepsis 34.43 19.78 47 26280 13720 34916884
Portal vein thrombosis 34.32 19.78 26 26301 3762 34926842
Weight increased 33.58 19.78 14 26313 93019 34837585
Secondary adrenocortical insufficiency 33.31 19.78 18 26309 1452 34929152
Guillain-Barre syndrome 32.85 19.78 31 26296 6056 34924548
Myasthenic syndrome 32.66 19.78 13 26314 518 34930086
Thyroiditis 32.63 19.78 21 26306 2341 34928263
Lymphocyte count decreased 32.61 19.78 60 26267 22562 34908042
Cortisol decreased 31.84 19.78 16 26311 1111 34929493
Metastases to bone 31.67 19.78 42 26285 11928 34918676
Stomatitis 31.05 19.78 86 26241 42428 34888176
Haemoptysis 30.88 19.78 76 26251 34930 34895674
Bleeding varicose vein 30.62 19.78 11 26316 329 34930275
Immune-mediated hepatic disorder 30.31 19.78 15 26312 1008 34929596
Hypertension 30.31 19.78 191 26136 136252 34794352
Upper gastrointestinal haemorrhage 29.87 19.78 62 26265 25456 34905148
Hypoalbuminaemia 29.60 19.78 41 26286 12133 34918471
Myasthenia gravis 29.43 19.78 31 26296 6909 34923695
Hospitalisation 29.40 19.78 4 26323 56898 34873706
Hepatic rupture 29.34 19.78 7 26320 45 34930559
Pulmonary toxicity 28.85 19.78 29 26298 6118 34924486
Somnolence 28.55 19.78 25 26302 111091 34819513
Anxiety 28.54 19.78 20 26307 99408 34831196
Cholangitis sclerosing 28.35 19.78 16 26311 1405 34929199
Lung disorder 28.17 19.78 73 26254 34623 34895981
Thrombophlebitis migrans 28.10 19.78 9 26318 188 34930416
Primary adrenal insufficiency 28.01 19.78 7 26320 56 34930548
Neutropenia 28.00 19.78 208 26119 156570 34774034
Nasopharyngitis 27.83 19.78 9 26318 69959 34860645
Loss of consciousness 27.41 19.78 14 26313 82653 34847951
Product use issue 27.22 19.78 7 26320 63209 34867395
Joint swelling 27.03 19.78 6 26321 59884 34870720
Nephrotic syndrome 26.41 19.78 30 26297 7273 34923331
Haemophagocytic lymphohistiocytosis 26.17 19.78 40 26287 12933 34917671
Thrombocytopenia 25.51 19.78 203 26124 156044 34774560
Gastrointestinal perforation 25.43 19.78 22 26305 3841 34926763
Drug intolerance 24.89 19.78 7 26320 59563 34871041
Small cell lung cancer recurrent 24.77 19.78 4 26323 0 34930604
Immune-mediated myocarditis 24.66 19.78 12 26315 777 34929827
Transaminases increased 24.47 19.78 59 26268 26764 34903840
Sepsis 24.31 19.78 211 26116 166350 34764254
Lymphocytic hypophysitis 24.05 19.78 9 26318 303 34930301
Tumour pain 23.66 19.78 13 26314 1084 34929520
Hypercalcaemia 23.53 19.78 42 26285 15426 34915178
Meningitis 22.99 19.78 23 26304 4824 34925780
Headache 22.98 19.78 76 26251 200559 34730045
Large intestine perforation 22.74 19.78 30 26297 8473 34922131
Autoimmune myocarditis 22.67 19.78 8 26319 227 34930377
Autoimmune haemolytic anaemia 22.56 19.78 22 26305 4474 34926130
Skin disorder 22.17 19.78 38 26289 13517 34917087
Alpha 1 foetoprotein decreased 22.00 19.78 4 26323 4 34930600
Pneumothorax 21.89 19.78 46 26281 19046 34911558
Plasma cell myeloma 21.61 19.78 3 26324 42034 34888570
Serous retinal detachment 21.23 19.78 10 26317 602 34930002
Cardiac failure congestive 21.06 19.78 19 26308 83251 34847353
Limbic encephalitis 20.99 19.78 9 26318 434 34930170
Hyperbilirubinaemia 20.99 19.78 42 26285 16801 34913803
Electrocardiogram QT prolonged 20.87 19.78 3 26324 40949 34889655
International normalised ratio increased 20.84 19.78 5 26322 47322 34883282
Urinary tract infection 20.74 19.78 121 26206 83960 34846644
Incorrect dose administered 20.57 19.78 3 26324 40512 34890092
Musculoskeletal stiffness 20.42 19.78 5 26322 46675 34883929
Agitation 20.13 19.78 9 26318 57390 34873214
Alpha 1 foetoprotein increased 19.86 19.78 10 26317 697 34929907

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypothyroidism 681.61 19.31 402 44199 51990 79647797
Disease progression 636.61 19.31 641 43960 183721 79516066
Pneumonitis 596.53 19.31 390 44211 60470 79639317
Neutrophil count decreased 553.51 19.31 442 44159 93517 79606270
Interstitial lung disease 495.63 19.31 448 44153 112152 79587635
Febrile neutropenia 481.15 19.31 618 43983 230381 79469406
Adrenal insufficiency 449.31 19.31 248 44353 28239 79671548
Proteinuria 421.47 19.31 249 44352 32253 79667534
Hyperthyroidism 391.02 19.31 208 44393 22001 79677786
Pyrexia 339.92 19.31 987 43614 677722 79022065
Colitis 338.81 19.31 300 44301 73007 79626780
Anaemia 335.73 19.31 756 43845 444259 79255528
Hepatic function abnormal 306.04 19.31 283 44318 72824 79626963
Death 303.88 19.31 845 43756 565669 79134118
Myocarditis 277.77 19.31 165 44436 21568 79678219
Ascites 277.30 19.31 272 44329 75290 79624497
Platelet count decreased 247.55 19.31 413 44188 194251 79505536
Immune-mediated enterocolitis 228.33 19.31 90 44511 4740 79695047
Encephalitis 217.67 19.31 123 44478 14637 79685150
Immune-mediated hepatitis 204.50 19.31 77 44524 3579 79696208
Drug interaction 194.52 19.31 9 44592 415174 79284613
Oesophageal varices haemorrhage 183.10 19.31 74 44527 4162 79695625
Myelosuppression 176.35 19.31 160 44441 40136 79659651
Cholangitis 171.11 19.31 100 44501 12676 79687111
Toxicity to various agents 164.50 19.31 21 44580 421519 79278268
Drug ineffective 150.00 19.31 234 44367 1080679 78619108
Myositis 150.00 19.31 107 44494 19061 79680726
Type 1 diabetes mellitus 148.29 19.31 74 44527 6845 79692942
Neutropenic sepsis 145.78 19.31 121 44480 26943 79672844
Tumour haemorrhage 144.12 19.31 62 44539 4082 79695705
Enterocolitis 134.72 19.31 90 44511 14422 79685365
Metastases to central nervous system 134.13 19.31 94 44507 16281 79683506
Lymphocyte count decreased 130.04 19.31 146 44455 47143 79652644
Aspartate aminotransferase increased 127.66 19.31 256 44345 138385 79561402
Drug intolerance 126.02 19.31 5 44596 264114 79435673
Product dose omission issue 124.16 19.31 3 44598 247534 79452253
Hepatic failure 122.67 19.31 161 44440 61051 79638736
Decreased appetite 122.42 19.31 445 44156 341973 79357814
Autoimmune hepatitis 121.40 19.31 78 44523 11705 79688082
Joint swelling 121.15 19.31 11 44590 288635 79411152
Embolism 120.94 19.31 83 44518 13899 79685888
Neutropenia 118.55 19.31 392 44209 287318 79412469
Thrombocytopenia 117.96 19.31 371 44230 264888 79434899
Alanine aminotransferase increased 114.06 19.31 269 44332 162301 79537486
Immune-mediated lung disease 112.92 19.31 44 44557 2246 79697541
White blood cell count decreased 112.52 19.31 293 44308 187995 79511792
Systemic immune activation 112.43 19.31 25 44576 159 79699628
Condition aggravated 112.28 19.31 71 44530 501053 79198734
Hypophysitis 111.84 19.31 52 44549 4114 79695673
Peripheral sensory neuropathy 109.51 19.31 76 44525 12957 79686830
Therapy partial responder 109.03 19.31 85 44516 17312 79682475
Radiation pneumonitis 108.41 19.31 50 44551 3883 79695904
Nephritis 108.18 19.31 51 44550 4163 79695624
Liver disorder 107.43 19.31 165 44436 72252 79627535
Hypokalaemia 107.25 19.31 244 44357 143796 79555991
Drug hypersensitivity 107.11 19.31 19 44582 298897 79400890
Hepatitis 106.16 19.31 143 44458 55584 79644203
Hypopituitarism 105.69 19.31 47 44554 3352 79696435
Hyponatraemia 105.49 19.31 276 44325 177572 79522215
Pain 104.52 19.31 145 44456 703657 78996130
Sepsis 102.95 19.31 358 44243 269070 79430717
Varicose vein ruptured 101.97 19.31 22 44579 119 79699668
Pneumonia 95.26 19.31 663 43938 659583 79040204
Tumour hyperprogression 93.66 19.31 22 44579 184 79699603
Tubulointerstitial nephritis 93.28 19.31 111 44490 38124 79661663
Abdominal discomfort 91.88 19.31 15 44586 250712 79449075
Swelling 91.61 19.31 8 44593 216703 79483084
Weight increased 90.37 19.31 22 44579 277364 79422423
Hepatic encephalopathy 88.57 19.31 87 44514 24079 79675708
Erythema multiforme 87.00 19.31 75 44526 17576 79682211
Nasopharyngitis 86.99 19.31 18 44583 253863 79445924
Immune-mediated encephalitis 86.88 19.31 25 44576 490 79699297
Peripheral swelling 86.64 19.31 22 44579 269595 79430192
Autoimmune colitis 86.50 19.31 33 44568 1590 79698197
Overdose 86.14 19.31 4 44597 184202 79515585
Blood bilirubin increased 85.98 19.31 142 44459 66090 79633697
Varices oesophageal 85.82 19.31 49 44552 5942 79693845
Arthropathy 85.67 19.31 3 44598 177108 79522679
Adrenocorticotropic hormone deficiency 84.16 19.31 31 44570 1354 79698433
Thyroiditis 80.64 19.31 43 44558 4562 79695225
Product use issue 80.44 19.31 11 44590 209811 79489976
Therapeutic product effect decreased 78.48 19.31 3 44598 163860 79535927
Skin candida 78.46 19.31 33 44568 2054 79697733
Constipation 76.28 19.31 337 44264 282713 79417074
Neuropathy peripheral 75.43 19.31 211 44390 141094 79558693
Tumour rupture 75.25 19.31 22 44579 457 79699330
Rash maculo-papular 73.82 19.31 121 44480 55957 79643830
Drug-induced liver injury 73.04 19.31 132 44469 65985 79633802
Cytokine release syndrome 72.59 19.31 95 44506 35903 79663884
Musculoskeletal stiffness 69.94 19.31 8 44593 175000 79524787
Metastases to meninges 69.83 19.31 36 44565 3565 79696222
Contraindicated product administered 68.84 19.31 5 44596 157533 79542254
Haemophagocytic lymphohistiocytosis 67.99 19.31 72 44529 21765 79678022
Myasthenia gravis 67.75 19.31 52 44549 10347 79689440
Guillain-Barre syndrome 67.73 19.31 49 44552 8916 79690871
Meningitis 67.04 19.31 50 44551 9532 79690255
Rheumatoid arthritis 66.98 19.31 17 44584 208453 79491334
Encephalitis autoimmune 65.85 19.31 30 44571 2264 79697523
Pleural effusion 65.23 19.31 204 44397 145058 79554729
Fulminant type 1 diabetes mellitus 64.41 19.31 26 44575 1457 79698330
Fall 64.07 19.31 109 44492 487520 79212267
Dizziness 61.81 19.31 126 44475 526315 79173472
Autoimmune haemolytic anaemia 61.49 19.31 45 44556 8335 79691452
Hypomagnesaemia 61.44 19.31 101 44500 46810 79652977
Encephalopathy 61.43 19.31 124 44477 67273 79632514
Hypertension 58.35 19.31 350 44251 330642 79369145
Discomfort 57.85 19.31 3 44598 125614 79574173
Metastases to bone 56.44 19.31 69 44532 24358 79675429
Paraneoplastic neurological syndrome 56.41 19.31 12 44589 60 79699727
Inappropriate schedule of product administration 56.27 19.31 5 44596 133623 79566164
Diarrhoea 56.18 19.31 744 43857 879745 78820042
Hyperhidrosis 55.61 19.31 9 44592 151483 79548304
Sinusitis 55.46 19.31 20 44581 195481 79504306
Mucosal inflammation 55.06 19.31 127 44474 75453 79624334
Tumour necrosis 54.75 19.31 25 44576 1897 79697890
Hyperglycaemia 53.25 19.31 120 44481 70215 79629572
Mobility decreased 53.03 19.31 4 44597 122171 79577616
Maternal exposure during pregnancy 52.69 19.31 7 44594 136531 79563256
Small intestinal obstruction 51.95 19.31 70 44531 27202 79672585
Treatment failure 50.86 19.31 16 44585 170470 79529317
Somnolence 49.24 19.31 37 44564 238944 79460843
Portal vein thrombosis 49.00 19.31 34 44567 5793 79693994
Arthralgia 48.60 19.31 161 44440 571642 79128145
Headache 48.39 19.31 195 44406 653577 79046210
Tumour pseudoprogression 48.01 19.31 17 44584 662 79699125
Pneumothorax 46.94 19.31 68 44533 28255 79671532
Cortisol decreased 45.86 19.31 23 44578 2149 79697638
Hypoalbuminaemia 45.75 19.31 58 44543 21239 79678548
Transaminases increased 45.73 19.31 94 44507 51649 79648138
Tremor 45.59 19.31 19 44582 170064 79529723
Cholangitis sclerosing 44.43 19.31 24 44577 2613 79697174
Pemphigus 43.96 19.31 3 44598 99579 79600208
Urinary occult blood 43.83 19.31 8 44593 14 79699773
Adrenal disorder 43.14 19.31 22 44579 2129 79697658
Immune-mediated hepatic disorder 43.11 19.31 20 44581 1574 79698213
Haemoptysis 42.90 19.31 96 44505 55903 79643884
Cerebral infarction 42.77 19.31 85 44516 45591 79654196
Acute kidney injury 42.71 19.31 461 44140 518943 79180844
Nephrotic syndrome 42.39 19.31 41 44560 11133 79688654
General physical health deterioration 42.23 19.31 281 44320 274957 79424830
Pericardial effusion 42.05 19.31 85 44516 46152 79653635
Tumour pain 41.76 19.31 22 44579 2277 79697510
Asthma 41.52 19.31 12 44589 135083 79564704
Tumour thrombosis 41.49 19.31 11 44590 157 79699630
Stomatitis 39.67 19.31 175 44426 146582 79553205
Liver carcinoma ruptured 39.64 19.31 11 44590 188 79699599
Insomnia 38.83 19.31 48 44553 245122 79454665
Gastrointestinal perforation 38.48 19.31 30 44571 6107 79693680
Hypertransaminasaemia 38.34 19.31 40 44561 11884 79687903
Therapeutic product effect incomplete 37.67 19.31 16 44585 141629 79558158
COVID-19 37.43 19.31 181 44420 157493 79542294
Pulmonary toxicity 37.43 19.31 41 44560 12873 79686914
Anxiety 36.95 19.31 51 44550 248461 79451326
Hypersensitivity 36.84 19.31 56 44545 262183 79437604
Hydronephrosis 36.65 19.31 47 44554 17407 79682380
Heart rate increased 36.60 19.31 11 44590 120713 79579074
Secondary adrenocortical insufficiency 36.21 19.31 22 44579 2992 79696795
Blister 36.01 19.31 11 44590 119465 79580322
Hospitalisation 35.96 19.31 5 44596 94231 79605556
Immune-mediated pancreatitis 35.22 19.31 11 44590 288 79699499
Disseminated intravascular coagulation 35.13 19.31 68 44533 35774 79664013
Large intestine perforation 35.04 19.31 42 44559 14525 79685262
Oligoastrocytoma 35.02 19.31 7 44594 24 79699763
Muscle spasms 34.78 19.31 28 44573 174702 79525085
Contusion 34.74 19.31 20 44581 148756 79551031
Thrombophlebitis migrans 34.71 19.31 12 44589 435 79699352
Immune thrombocytopenia 34.36 19.31 46 44555 17759 79682028
Sleep disorder 34.01 19.31 4 44597 85673 79614114
Myasthenic syndrome 33.96 19.31 14 44587 828 79698959
Limbic encephalitis 33.44 19.31 14 44587 861 79698926
Immune-mediated myocarditis 32.85 19.31 15 44586 1138 79698649
Palpitations 32.57 19.31 15 44586 126595 79573192
Skin toxicity 32.47 19.31 31 44570 8283 79691504
Loss of consciousness 32.09 19.31 28 44573 167915 79531872
Incorrect dose administered 31.90 19.31 3 44598 76627 79623160
Angioedema 31.59 19.31 3 44598 76032 79623755
Hepatobiliary disease 31.53 19.31 13 44588 769 79699018
International normalised ratio increased 31.16 19.31 5 44596 84716 79615071
Ileus 31.09 19.31 54 44547 26157 79673630
Cytopenia 30.99 19.31 47 44554 20336 79679451
Bleeding varicose vein 30.90 19.31 12 44589 607 79699180
Blood pressure increased 30.79 19.31 44 44557 211316 79488471
Migraine 30.36 19.31 6 44595 87487 79612300
Polymyalgia rheumatica 30.24 19.31 23 44578 4514 79695273
Psoriatic arthropathy 30.09 19.31 4 44597 77995 79621792
Depression 29.77 19.31 47 44554 216743 79483044
Pancytopenia 29.61 19.31 176 44425 165569 79534218
Hypercalcaemia 29.56 19.31 66 44535 38364 79661423
Lipase increased 29.45 19.31 41 44560 16425 79683362
Metastases to liver 29.33 19.31 55 44546 28259 79671528
Febrile infection 29.26 19.31 20 44581 3326 79696461
Respiratory failure 29.12 19.31 187 44414 180724 79519063
Heart rate decreased 28.62 19.31 3 44598 70313 79629474
Pulmonary embolism 28.60 19.31 179 44422 171475 79528312
Urticaria 28.54 19.31 37 44564 185164 79514623
Amylase increased 28.09 19.31 33 44568 11176 79688611
Serous retinal detachment 28.04 19.31 13 44588 1021 79698766
Tumour lysis syndrome 27.98 19.31 49 44552 23890 79675897
Bradycardia 27.89 19.31 21 44580 135536 79564251
Autoimmune myocarditis 27.77 19.31 10 44591 409 79699378
Medication error 27.76 19.31 3 44598 68639 79631148
Nervous system disorder 27.61 19.31 52 44549 26804 79672983
Memory impairment 27.58 19.31 14 44587 111720 79588067
Biliary obstruction 27.48 19.31 22 44579 4652 79695135
Hyperbilirubinaemia 27.13 19.31 49 44552 24469 79675318
Enteritis 27.11 19.31 37 44564 14546 79685241
Agitation 26.94 19.31 11 44590 99704 79600083
Pyelonephritis 26.83 19.31 44 44557 20344 79679443
Metastases to lymph nodes 26.70 19.31 31 44570 10366 79689421
Cholecystitis 26.65 19.31 46 44555 22166 79677621
Swelling face 26.65 19.31 4 44597 71208 79628579
Neoplasm progression 26.40 19.31 76 44525 51606 79648181
Upper gastrointestinal haemorrhage 26.33 19.31 66 44535 41314 79658473
Hepatic rupture 26.20 19.31 7 44594 103 79699684
Fluid retention 25.94 19.31 4 44597 69805 79629982
Wheezing 25.41 19.31 17 44584 116647 79583140
Cancer pain 25.26 19.31 22 44579 5223 79694564
Muscular weakness 25.16 19.31 165 44436 160564 79539223
Rhinorrhoea 24.81 19.31 6 44595 76068 79623719
Lymphocytic hypophysitis 24.74 19.31 10 44591 562 79699225
Enterocolitis infectious 24.73 19.31 17 44584 2852 79696935
Skin disorder 24.67 19.31 57 44544 33886 79665901
Osteoarthritis 24.63 19.31 9 44592 87300 79612487
Cardiac failure congestive 24.57 19.31 26 44575 142376 79557411
Alpha 1 foetoprotein increased 24.57 19.31 11 44590 797 79698990
Peripheral motor neuropathy 24.52 19.31 18 44583 3349 79696438
Blood creatine phosphokinase increased 24.46 19.31 87 44514 66003 79633784
Electrocardiogram QT prolonged 24.37 19.31 10 44591 90376 79609411
Coma 24.26 19.31 13 44588 100636 79599151
Hallucination 23.92 19.31 9 44592 85736 79614051
Pulmonary haemorrhage 23.90 19.31 35 44566 14682 79685105
Subileus 23.84 19.31 22 44579 5632 79694155
Pain in extremity 23.70 19.31 114 44487 364424 79335363
Haemoglobin decreased 23.66 19.31 56 44545 222063 79477724
Metastases to lung 23.63 19.31 39 44562 18124 79681663
Subacute cutaneous lupus erythematosus 23.62 19.31 18 44583 3543 79696244
Blood glucose increased 23.41 19.31 18 44583 114957 79584830
Malignant neoplasm progression 23.39 19.31 143 44458 135847 79563940
Renal impairment 22.92 19.31 159 44442 157624 79542163
Gait inability 22.77 19.31 3 44598 58914 79640873
Pancreatitis 22.64 19.31 87 44514 68488 79631299
Blood creatinine increased 22.37 19.31 156 44445 154901 79544886
Lactic acidosis 22.08 19.31 6 44595 70353 79629434
Haemobilia 22.05 19.31 9 44592 519 79699268
Duodenal ulcer perforation 22.03 19.31 5 44596 66206 79633581
Influenza 21.99 19.31 24 44577 129582 79570205
Tumour inflammation 21.95 19.31 5 44596 36 79699751
Immune-mediated nephritis 21.35 19.31 9 44592 563 79699224
Portal hypertension 21.35 19.31 23 44578 7085 79692702
Diabetic ketoacidosis 21.26 19.31 54 44547 34068 79665719
Febrile bone marrow aplasia 21.19 19.31 31 44570 12989 79686798
Intestinal metastasis 21.12 19.31 8 44593 378 79699409
Protein urine 20.46 19.31 12 44589 1530 79698257
Gastrooesophageal reflux disease 20.37 19.31 17 44584 104229 79595558
Wrong technique in product usage process 20.20 19.31 8 44593 73867 79625920
Cardiac failure 20.16 19.31 152 44449 154690 79545097
Blood thyroid stimulating hormone increased 20.16 19.31 26 44575 9682 79690105
Off label use 20.15 19.31 656 43945 906559 78793228
Pemphigoid 20.08 19.31 33 44568 15282 79684505
Plasma cell myeloma 19.91 19.31 3 44598 53256 79646531
Nasal congestion 19.79 19.31 9 44592 76543 79623244
Haematocrit decreased 19.67 19.31 5 44596 61307 79638480
Hepatic enzyme increased 19.48 19.31 46 44555 182564 79517223
Meningism 19.44 19.31 9 44592 705 79699082
Metastases to adrenals 19.38 19.31 11 44590 1319 79698468

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01FF05 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors
MeSH PA D000970 Antineoplastic Agents
MeSH PA D000074322 Antineoplastic Agents, Immunological
MeSH PA D000082082 Immune Checkpoint Inhibitors
FDA CS M0001352 Antibodies
FDA CS M0001357 Antibodies, Monoclonal
FDA CS M0556300 Antibodies, Monoclonal, Humanized
FDA MoA N0000191259 Programmed Death Receptor-1-directed Antibody Interactions
FDA EPC N0000191260 Programmed Death Receptor-1 Blocking Antibody

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Transitional cell carcinoma indication 27090000 DOID:2671
Liver cell carcinoma indication 109841003 DOID:684
Germline BRCA-mutated, HER2-negative metastatic breast cancer indication 767444009
Metastatic non-small cell lung cancer indication 457721000124104
Extensive stage primary small cell carcinoma of lung indication 683991000119103




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Programmed cell death 1 ligand 1 CD molecules ANTIBODY BINDING Kd 9.39 SCIENTIFIC LITERATURE DRUG LABEL

External reference:

IDSource
52CMI0WC3Y UNII
4035750 VANDF
C4055433 UMLSCUI
CHEMBL3707227 ChEMBL_ID
D10773 KEGG_DRUG
DB11595 DRUGBANK_ID
9814 INN_ID
7990 IUPHAR_LIGAND_ID
1792776 RXNORM
240980 MMSL
31671 MMSL
d08438 MMSL
016856 NDDF
719371003 SNOMEDCT_US
763505003 SNOMEDCT_US
C000594389 MESH_SUPPLEMENTAL_RECORD_UI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
TECENTRIQ HUMAN PRESCRIPTION DRUG LABEL 1 50242-917 INJECTION, SOLUTION 1200 mg INTRAVENOUS BLA 31 sections
TECENTRIQ HUMAN PRESCRIPTION DRUG LABEL 1 50242-917 INJECTION, SOLUTION 1200 mg INTRAVENOUS BLA 31 sections
TECENTRIQ HUMAN PRESCRIPTION DRUG LABEL 1 50242-918 INJECTION, SOLUTION 840 mg INTRAVENOUS BLA 31 sections
TECENTRIQ HUMAN PRESCRIPTION DRUG LABEL 1 50242-918 INJECTION, SOLUTION 840 mg INTRAVENOUS BLA 31 sections